Review anchor
Bacterial penicillin-binding protein
PROTEIN FAMILY · Bacteria
As of 2026-09-13
Evidence Snapshot
Bacterial penicillin-binding protein
CHEMBL2354204
PROTEIN FAMILY
Bacteria
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Bacterial penicillin-binding protein as ChEMBL target CHEMBL2354204, mapped to UniProt P24228. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2354204
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P24228
D-alanyl-D-alanine carboxypeptidase DacB
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Bacterial penicillin-binding protein matters
Bacterial penicillin-binding protein is reviewed as D-alanyl-D-alanine carboxypeptidase DacB (UniProt P24228); Bacterial penicillin-binding protein shows approved-linked disease relevance led by bacterial disease. 5 more disease programs remain visible in the same review block.; 38 linked drugs keep this evidence frame grounded.; the current evidence base includes 0 approved drugs, 1 compound, and 1 assay.
Protein context
D-alanyl-D-alanine carboxypeptidase DacB
D-alanyl-D-alanine carboxypeptidase DacB Sequence length is 477 aa.
Review this target as Bacterial penicillin-binding protein, mapped to UniProt P24228. ChEMBL maps the protein component as D-alanyl-D-alanine carboxypeptidase DacB. Sequence length is 477 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P24228
Protein
Disease context
bacterial disease
Bacterial penicillin-binding protein shows approved-linked disease relevance led by bacterial disease. 5 more disease programs remain visible in the same review block. 38 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include AMOXICILLIN, AMPICILLIN, AZTREONAM.
Start review with bacterial disease because it currently carries approved-linked support. Linked drugs include AMOXICILLIN, AMPICILLIN, AZTREONAM, CEFACLOR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
38 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 0 approved drugs, 1 compound, and 1 assay for this target.
Activity source · ChEMBL 36 via Core EngineSource Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Bacterial penicillin-binding protein matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P24228, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why bacterial disease is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
1
Total Compounds
1
Total Assays
0
Approved Drugs
-
Activity Types
pChEMBL Activity Distribution
Source Header